Search or choose
Find the right test or package.
PDL-1 SP263 Ventana
PDL-1 SP263 Ventana is an immunohistochemistry (IHC) test used to assess the expression of programmed death-ligand 1 (PDL1) protein in tumor tissue samples. It utilizes the Ventana SP263 assay for assessing PD-L1 expression in various clinical settings. The te...
DiagnosticsLab test
Know more about this test
PDL-1 SP263 Ventana is an immunohistochemistry (IHC) test used to assess the expression of programmed death-ligand 1 (PDL1) protein in tumor tissue samples. It utilizes the Ventana SP263 assay for assessing PD-L1 expression in various clinical settin...
Understanding PDL-1 SP263 Ventana
PDL-1 SP263 Ventana is an immunohistochemistry (IHC) test used to assess the expression of programmed death-ligand 1 (PDL1) protein in tumor tissue samples. It utilizes the Ventana SP263 assay for assessing PD-L1 expression in various clinical settings. The test is commonly used to determine eligibility for immunotherapy treatment with pembrolizumab (Keytruda) in patients with non-small cell lung cancer (NSCLC) and urothelial carcinoma. It helps guide treatment decisions by identifying patients who are likely to be...
What does PDL-1 SP263 Ventana measure?
PDL-1 SP263 Ventana is an immunohistochemistry (IHC) test used to assess the expression of programmed death-ligand 1 (PDL1) protein in tumor tissue samples. It utilizes the Ventana SP263 assay for assessing PD-L1 expression in various clinical settings. The test is commonly used to determine eligibility for immunotherapy treatment with pembrolizumab (Keytruda) in patients with non-small cell lung cancer (NSCLC) and urothelial carcinoma. It helps guide treatment decisions by identifying patients who are likely to be...
Related parameters
How does home sample collection work?
Select slot
Pick a convenient time.
Phlebotomist visit
A trained expert arrives home.
Safe testing
Samples move through the lab process.
Digital reports
Reports are delivered online.